abstract: BACKGROUND: Catheter ablation of the cavo-tricuspid isthmus is rapidly becoming the first line of treatment in the management of @entity956 . The standard procedure is usually performed under fluoroscopy guidance and relays on multisite endocardial recordings to assess the completeness of the isthmus conduction block. Despite the high rate of success there is, at follow-up, a considerable number of recurrences which could reflect the limitations of conventional assessment of conduction block across the isthmus. This new non-fluoroscopic mapping system allowing high density mapping along the entire length of the ablation line, could provide a more accurate way of verifying complete conduction block. The aim of the present study was to describe our overall results and long-term follow-up using a three-dimensional mapping system to guide radiofrequency ablation of typical @entity956 . METHODS: A multipoint three-dimensional map of the cavo-tricuspid isthmus, septal and lateral atrial wall was performed in 87 @entity1 prior to and following ablation for typical @entity956 . Evidence of persisting gaps in the line of block was identified by visual inspection of the color-coded activation maps and these sites were re-ablated. The conduction sequence was also assessed with conventional bidirectional pacing and recording. The assess the reduction in fluoroscopy time, two groups of @entity1 were compared: group A (14 @entity1 ) in whom the entire mapping-ablation procedure was guided by the three-dimensional system (Carto, Biosense-Webster, Diamond Bar, CA, USA) and group B (32 @entity1 ) in whom the same protocol was used but the procedure was guided by standard fluoroscopic imaging. RESULTS: Acute success was achieved in every @entity1 . During bilateral isthmus pacing, the mean local activation time increased from 20.3 +/- 13.3 ms pre-ablation to 148.3 +/- 53.2 ms (p < 0.01) post-ablation with a mean difference of 120 +/- 31 ms. In 11 @entity1 (9.2%) there was evidence of persisting conduction across the line of block despite evidence of reverse activation of the cavo-tricuspid isthmus by conventional pacing. A gap in the ablation line was identified and re-ablated. At a mean follow-up of 16.3 +/- 2.2 months, there were 5 (4.2%) recurrences of @entity956 (10%) recurrences of isolated @entity955 . Four of the 5 recurrences occurred in @entity1 in whom ablation was guided by conventional fluoroscopy (group B). The fluoroscopy time was 4.2 +/- 1.5 min in group A and 27.2 +/- 8.2 min in group B (p < 0.001). CONCLUSIONS: Multipoint mapping of the ablation line following radiofrequency ablation of typical @entity956 performed using the Carto system allows a more accurate assessment of the isthmus conduction block. This has the potential to reduce the recurrence rate to the level observed for other @entity4710 .

title: Usefulness of three-dimensional non-fluoroscopic mapping in the ablation of typical XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity4710 :: ('MESH:D013617', 'Disease') :: ['supraventricular tachycardias']

entities_list: @entity956 :: ('MESH:D001282', 'Disease') :: ['atrial flutter', 'atrial flutter and 12']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

answer: @entity956 :: (MESH:D001282,Disease) :: ['atrial flutter']


abstract: In C6 @entity35 @entity13 , we have investigated the relation between @entity519 and the presence of lipid droplets in the cytoplasm of viable cells adjacent to @entity39 . For this purpose, @entity35 were stereotaxically implanted with C6 cells. Experiments were carried out by the end of the @entity5 development. A multifluorescence staining protocol combined with digital image analysis was used to quantitatively study the spatial distribution of @entity519 cells ( @entity12184 ), blood perfusion (Hoechst 33342), total vascular bed (collagen type IV) and lipid droplets (Red Oil) in single frozen sections. All @entity5 (n=6) showed @entity39 , @entity12184 binding and lipid droplets. @entity12184 binding occurred at a mean distance of 114 microm from perfused vessels mainly around @entity39 . Lipid droplets were principally located in the @entity39 tissue. Some smaller droplets were also observed in part of the @entity12184 -binding cells surrounding @entity39 . Hence, lipid droplets appeared only in @entity519 cells adjacent to @entity39 , at an approximate distance of 181 microm from perfused vessels. In conclusion, our results show that severe @entity519 cells accumulated small lipid droplets. However, a 100% colocalisation of @entity519 and lipid droplets does not exist. Thus, lipid droplets cannot be considered as a surrogate marker of @entity519 , but rather of severe, @entity519 .

title: XXXX binding in C6 @entity35 @entity13 : relation with lipid droplet detection.

entities_list: @entity13 :: ('MESH:C564230', 'Disease') :: ['brain glioma']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrotic', 'necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour', 'tumours']

entities_list: @entity519 :: ('MESH:D000860', 'Disease') :: ['prenecrotic hypoxia', 'hypoxic', 'hypoxia']

entities_list: @entity12184 :: ('MESH:C033815', 'Chemical') :: ['Pimonidazole', 'pimonidazole']

answer: @entity12184 :: (MESH:C033815,Chemical) :: ['Pimonidazole']


abstract: Trophoblast cell migration is unusual in epitheliochorial placentae but occurs in placentomes of @entity291 as "restricted" trophoblast invasion of binucleated trophoblast giant cells (TGC). Migration may be induced by integrin binding to the extracellular matrix initiating two pathways: (1) conformational changes of the @entity11296 cytoskeleton induced by an accumulation of its associated proteins and (2) integrin-dependent phosphorylation of various protein kinases. In @entity291 placentomes, @entity11296 , its associated proteins (alpha-actinin, @entity62868 ) and a key protein kinase of the signal transduction cascade (phosphorylated mitogen-activated protein kinase, pMAPK) were localized by immunogold- @entity575 enhancement and immunoperoxidase staining at the light- and transmission electron-microscopical levels. Findings were confirmed by amplification of specific mRNA transcripts by reverse transcriptase/polymerase chain reaction. @entity11296 and alpha-actinin were co-localized apically in mononuclear trophoblast cells, along the cytoplasmic membrane of TGC and apically in maternal crypt cells. The @entity11296 and alpha-actinin immunoreaction occurred as a band of electron-dense particles beneath the cytoplasmic membrane. @entity62868 labelling was membrane-associated in TGC and in fetal and maternal endothelial cells. MAPK was observed as nuclear clusters in both kinds of trophoblast cells and was less dense in single uterine epithelial cells. Most MAPK immunoreactivity was detected in the nuclei of the trophoblast epithelium but was also sometimes membrane-associated in the cytoplasm. Thus, @entity11296 , alpha-actinin, MAPK and @entity62868 may be involved in the regulation of TGC migration. "Restricted" trophoblast invasion could serve as a model for invasive processes.

title: Cytoskeletal filaments and associated proteins during restricted trophoblast invasion in XXXX placentomes: light and transmission electron microscopy and RT-PCR.

answer: @entity291 :: (9913,Species) :: ['bovine']


abstract: OBJECTIVE: To examine the role of immune complexes in the prostanoid metabolism of glomerular capillary endothelial cells (EC) and platelets in @entity1988 . Heat aggregated IgG (HA-IgG), instead of immune complexes, was incubated using an in vitro coculture system with @entity1 umbilical vein EC, instead of glomerular capillary EC, and platelets. The effect of complement component @entity6300 and a novel @entity8304 -type @entity2404 (TXA2) synthetase inhibitor, @entity33064 , on this prostanoid metabolism change was also investigated. METHODS: EC monolayers (1.5x10(5) cells/well) were incubated with various concentrations of HA-IgG, monomeric IgG, or medium alone for 1 h at 37 degrees C, and then incubated with platelet suspensions (1x10(8) cells/ml) for various times. Concentrations of TXB2 and @entity9077 ( @entity9077 ), the stable hydrolysis products of @entity3447 and @entity4770 (PGI2), respectively, released in the supernatants were measured by ELISA. RESULTS: HA-IgG bound to EC monolayers produced TXB2 and @entity9077 in a concentration dependent manner and much more than monomeric IgG or medium alone did. However, the production of @entity9077 stimulated with HA-IgG was much lower than that of TXB2, indicating a large imbalance between TXA2 and PGI2. Preincubation of HA-IgG with purified @entity6300 partially suppressed the production of TXB2, but not that of @entity9077 . @entity33064 suppressed the production of TXB2 completely, but by sharp contrast, it dramatically increased the production of @entity9077 from EC and platelets by HA-IgG. CONCLUSION: The large imbalance of TXA2 and PGI2 produced by the interaction of EC, immune complexes, and platelets may be associated with alterations in glomerular pathological findings and hemodynamics mediated by immune complexes in @entity1988 . @entity6300 and a TXA2 synthetase inhibitor may improve the abnormal prostanoid metabolism change of @entity1988 .

title: Production of XXXX and @entity4770 affected by interaction of heat aggregated IgG, endothelial cells, and platelets in @entity1988 .

entities_list: @entity2404 :: ('MESH:D013928', 'Chemical') :: ['thromboxane A2']

entities_list: @entity8304 :: ('MESH:C029899', 'Chemical') :: ['imidazole']

entities_list: @entity1988 :: ('MESH:D008181', 'Disease') :: ['lupus nephritis']

entities_list: @entity4770 :: ('MESH:D011464', 'Chemical') :: ['prostaglandin I2']

entities_list: @entity9077 :: ('MESH:D015121', 'Chemical') :: ['6-keto-prostaglandin F(1alpha)', '6-keto-PGF(1alpha)']

answer: @entity2404 :: (MESH:D013928,Chemical) :: ['thromboxane A2']


abstract: UNASSIGNED: Illegal drugs exacerbate global social challenges such as @entity734 , mental health issues and violent crime. Police and customs officials often rely on specially-trained sniffer @entity235 , which act as sensitive biological detectors to find concealed illegal drugs. However, the @entity235 "alert" is no longer sufficient evidence to allow a search without a warrant or additional probable cause because @entity835 has been legalized in two US states and is decriminalized in many others. Retraining @entity235 to recognize a narrower spectrum of drugs is difficult and training new @entity235 is time consuming, yet there are no analytical devices with the portability and sensitivity necessary to detect substance-specific chemical signatures. This means there is currently no substitute for sniffer @entity235 . Here we describe an insect screening procedure showing that the western @entity5157 ( @entity5157 ) can sense volatiles associated with pure samples of @entity4521 and @entity2072 . We developed a portable electroantennographic device for the on-site measurement of volatile perception by these insects, and found a positive correlation between @entity5157 antennal responses and the concentration of specific drugs in test samples. Furthermore, we tested the ability of @entity5157 to learn the scent of @entity4521 and trained them to show a reliable behavioral response in the presence of a highly-diluted scent of pure @entity4521 . Trained @entity5157 could therefore be used to complement or replace the role of sniffer @entity235 as part of an automated drug detection system. Insects are highly sensitive to volatile compounds and provide an untapped resource for the development of biosensors. Automated conditioning as presented in this study could be developed as a platform for the practical detection of illicit drugs using insect-based sensors.

title: Detection of Illicit Drugs by Trained XXXX ( @entity5157 ).

entities_list: @entity835 :: ('MESH:D002189', 'Disease') :: ['cannabis']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['substance addiction']

entities_list: @entity5157 :: ('7460', 'Species') :: ['honeybee', 'Apis mellifera', 'honeybees']

answer: @entity5157 :: (7460,Species) :: ['Honeybees']


abstract: UNASSIGNED: 243 Background: Safety-net hospitals are at higher risk of poor @entity5 care and vary in levels of quality performance. Types of quality problems may differ and require different interventions. We undertook this study to identify organizational factors affecting quality and assess the early findings of the innovation's impact on hand-offs between specialists. METHODS: As part of a RCT testing a web-based tracking and feedback innovation to close referral loops, new @entity0 cases are rapidly ascertained, and post-surgical medical and radiation oncologist visits are assessed. Surgeons are alerted to @entity1 who do not show to oncology visits to stimulate action. Of 153 enrolled @entity1 (98 Intervention/ 55 Control), 4% are white. In addition, we conducted 90 key informant interviews in 9 safety-net hospitals in the NYC metropolitan area and performed a qualitative comparative analysis (QCA), a method to assess causal complexity, to identify organizational factors associated with poor quality. RESULTS: No-shows at oncology appointments triggering surgeon feedback occurred for 5/98 (5%) new @entity0 @entity1 . QCA revealed 6 conditions associated with poor quality-defined as underuse of needed adjuvant treatment: information sharing; follow-up; system support; @entity1 -centered culture; flexibility and private practice. All high-performing hospitals had a @entity1 -centered culture, strong follow-up approaches and shared information. Some of these high-quality sites had robust system support while others had creative workarounds (flexibility) or were responsive to their private practice @entity1 . Overall, these pathways had high consistency (.88) and coverage (.72). Only hospitals with both poor follow-up and system support activated the web-based feedback. CONCLUSIONS: Safety-net hospitals with poor follow-up capabilities may benefit from an innovation designed to improve hand-offs across specialties. This trial continues to accrue; we are monitoring the innovation's effectiveness. CLINICAL TRIAL INFORMATION: NCT01544374.

title: What fixes can improve XXXX care quality at safety-net hospitals?

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['quality cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: The treatment of non-conductive olfactory disorders is to a large extent an unsolved problem. This proof-of-concept study focused on possible effects of the @entity1024 ( @entity143 ) antagonist @entity66988 . Potential mechanisms for the hypothesized effect included reduced feedback inhibition in the olfactory bulb as a consequence of @entity143 antagonistic actions and antagonism of an excitotoxic action of @entity2227 . A total of 77 consecutive @entity1 with non-conductive olfactory disorders were included in the study. Fifty-one @entity1 received @entity66988 for 4 weeks (120 mg/day); 26 controls matched for age, gender and duration of olfactory loss were treated with @entity17562 for the same length of time (400 mg/day). Olfactory sensitivity was evaluated before and after treatment. Testing included assessment of @entity10439 odor threshold and odor identification. When compared to baseline, treatment with @entity66988 improved both odor thresholds (p = 0.005) and odor identification (p = 0.042) in anosmic @entity1 . In hyposmic @entity1 it significantly improved odor identification ability (p = 0.041). In contrast, @entity17562 had no significant effect on olfactory function. These results indicate that @entity66988 appears to be effective for the treatment of @entity4838 .

title: The quinoxaline derivative XXXX in the treatment of @entity4838 : a proof-of-concept study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1024 :: ('CHEBI:31882', 'Chemical') :: ['N-methyl-D-aspartate']

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

entities_list: @entity66988 :: ('MESH:C000957', 'Chemical') :: ['caroverine']

entities_list: @entity17562 :: ('MESH:D019287', 'Chemical') :: ['zinc sulfate']

entities_list: @entity4838 :: ('MESH:D000857', 'Disease') :: ['non-conductive smell disorders']

answer: @entity66988 :: (MESH:C000957,Chemical) :: ['caroverine']


abstract: An intravenous @entity413 tolerance test (IVGTT) was performed on 16 spontaneously @entity101 @entity35 (SHR) and 15 @entity35 -Kyoto @entity35 (WKY) by challenging them with an intravenous @entity413 load of 0.125 g/100 g body weight. Serum @entity413 and insulin were measured at 0, 15, 30, 60, 120, and 240 min. In a second experiment, oral @entity413 tolerance testing (OGTT) was performed with a @entity413 load of 170 mg/100 g body weight. Serum @entity413 and insulin were measured at 0, 30, 60, 120, and 240 min. A third experiment examined in vivo insulin-stimulated peripheral @entity413 uptake via the insulin suppression test. @entity413 (8 mg/kg/min), insulin (2.5 to 4.0 mU/kg/min), and @entity1943 (1 ng/kg/min) were infused for 3 h. Steady state serum @entity413 (SSSG) and serum insulin (SSSI) were determined at 0, 140, 160, and 180 min. IVGTT data indicated that serum @entity413 values were significantly increased in the WKY compared to the SHR at 15, 30, 60, and 120 min. @entity413 clearance rates between 15 and 60 min were significantly (P less than .0001) lower in WKY (0.65 +/- 0.07%/min) compared to SHR (1.91 +/- 0.17%/min). The SHR exhibited an exaggerated 15-min peak in insulin secretion that was lacking in the WKY in response to an intravenous @entity413 load. OGTT data also indicated that the area under the serum insulin curves was higher in the WKY than in the SHR (P less than .017). @entity1897 showed that despite comparable SSSI levels between the two strains, SSSG values were 31% higher in the SHR compared to the WKY (P less than .001). Thus, it appears that the WKY has a diminished insulin secretory capacity in response to a @entity413 load, while the SHR has lower tissue responsiveness to insulin's action.

title: Patterns of insulin secretion and responsiveness in @entity35 -Kyoto and spontaneously @entity101 XXXX .

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['Peripheral insulin sensitivity']

entities_list: @entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose', 'Glucose']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: This study was designed to evaluate the toxicological effect of dietary @entity14149 ( @entity4437 ) on the counts of intestinal bacteria and diversity of microorganisms in broilers. Plate counting and polymerase chain reaction-denaturing gradient gel electrophoresis (PCR-DGGE) assays were used. A total of 240 one-day-old avian broilers chicks were divided into four equal groups and kept on @entity4336 - @entity1460 basal diet along with supplementation of 0, 300, 600 and 900 mg/kg @entity4437 for 42 days. Samples were taken at 21 and 42 days of age during the experiment. The bacterial count results showed that dietary @entity4437 in the range of 300 to 900 mg/kg decreased the counts of Bifidobacterium spp. and Lactobacillus, increased @entity526 (E. coli) and Enterococcus spp. in the ileum and cecum. PCR-DGGE analysis showed that bacterial band numbers, profile similarity, and the Shannon index of the ileum and cecum were all decreased in the 300, 600, and 900 mg/kg groups at 21 and 42 days of age. In conclusion, dietary @entity4437 affected the amount and diversity of intestinal microbiota in the ileum and cecum of broilers. This finding implies that @entity4437 has toxicological effect on the intestinal ecosystem and, possibly functions.

title: Toxicological effects of dietary XXXX on intestinal microbiota.

entities_list: @entity14149 :: ('MESH:C022838', 'Chemical') :: ['nickel chloride']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli']

answer: @entity14149 :: (MESH:C022838,Chemical) :: ['nickel chloride']


abstract: BACKGROUND AND PURPOSE: After @entity5 morcellation, staging relies on clinical imaging. Our goal was to determine the size distribution of stage pT(3a) @entity1358 ( @entity1358 ) and whether evidence of extrarenal invasion is present on preoperative imaging. @entity1 AND METHODS: We selected @entity1 with organ-confined @entity1358 treated surgically from 1975 to 2002 and subsequently found to have stage pT(3a) disease. Preoperative radiologic imaging reports were reviewed for evidence of extrarenal @entity5 extension. RESULTS: Of the 1781 @entity1 treated surgically for pM(0) @entity1358 , 129 (7.2%) had pT(3a) disease. @entity5 size distributions were: 17 (13.2%) < or =4 cm, 38 (29.5%) >4 cm but < or =7 cm, and 74 (57.4%) >7cm. There were 6 @entity1 (4.7%) with extrarenal extension according to preoperative imaging. Of these, 2 (5.3%) had @entity5 >4 cm but < or =7cm, and 4 (5.4%) had @entity5 >7 cm. CONCLUSION: Many pT(3a) @entity5 are small, and the majority is understaged clinically. Thus, morcellation in these @entity1 would prevent accurate staging.

title: Potential underdetection of pT(3a) XXXX with laparoscopic morcellation.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'tumors']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['RCCs', 'RCC', 'renal-cell carcinomas']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['renal-cell carcinoma']


abstract: OBJECTIVE: @entity66771 is a 20-base phosphorothioate DNA oligonucleotide against @entity1 @entity10242 kinase, a downstream effector of ras oncogene function. @entity10242 kinase is a molecule in the MAP kinase signaling cascade which is essential for cellular proliferation, the overexpression of which leads to malignant expression. Activity of this compound was documented in a @entity1 with @entity43 in a Phase I study. METHODS: We evaluated @entity66771 at a dose of 4 mg/kg/day by continuous venous infusion, administered for 21 days q 4 weeks in 22 @entity1 with recurrent @entity43 in a standard two-stage Phase II design. Three @entity1 were ineligible; 19 @entity1 are evaluable for @entity137 and 16 for response. All @entity1 had previously received systemic therapy for @entity43 (6 had one and 13 had two prior regimens). @entity1 were treated with a median of two cycles and 79% of the @entity1 received >90% planned dose intensity. RESULTS: @entity66771 was well tolerated with no episodes of Grade 3 or 4 hematologic or biochemical ( @entity1011 , @entity6571 , @entity648 ) @entity137 . There were six episodes of grade 3 nonhematologic @entity137 in 4 @entity1 thought to be treatment related (lethargy 2; @entity448 1; @entity490 2; shortness of breath 1). No responses were seen in the 16 @entity1 who are evaluable for response; 4 had stable disease for a median of 3.8 months and 12 @entity1 had documented progressive disease. CONCLUSION: @entity66771 at 4 mg/kg/day as a single agent did not show activity in recurrent @entity43 .

title: Phase II study of @entity66771 ( @entity66771 ) in recurrent XXXX : an NCIC clinical trials group study (NCIC IND.116).

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'woman', 'human', 'patients']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin']

entities_list: @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

answer: @entity43 :: (MESH:D010051,Disease) :: ['epithelial ovarian cancer']


abstract: A case of superior @entity50 was reported. A 23-year-old male was admitted to our clinic on August 16, 1978, because of generalized @entity410 seizures. he had complained of severe @entity10 and high fever for about 7 days before admission, and on admission he was in slightly drowsy state. At that time, bilateral choked discs and bilateral abducens pareses were found without any other @entity51 . CT scan on his 1st hospital day revealed only slight compression of the ventricular system without any midline shift. On the 2nd hospital day, he developed @entity1269 , but his level of consciousness did not deteriorate as that of the previous day, demonstrating clear CSF by lumbar puncture. Right CAG on August 21 revealed delayed circulation, poor-filling of the cortical veins, and narrow superior sagittal sinus showing zigzag shaped margin. CT scan on August 22 showed multiple irregular high dense foci mainly in both parietal lobes and the shift to the left of the ventricular system. Besides, on enhanced CT scan, the so-called "empty triangle" sign was revealed with gyral enhancement. Although an increase of the shift of the ventricular system was demonstrated by the follow-up CT scans, he gradually improved and external decompression was necessitated no longer. He was discharged with slight weakness of the left upper limb after superior sagittal sinus showing good-filling on right CAG performed on September 27 and had been identified. As a result, it was confirmed that in case sinus @entity715 is doubted, follow-up study by CT scan would be significant for the choice of treatments as well as for its diagnosis at its each stage.

title: [A case report of superior XXXX --evaluation of computed tomographic findings in diagnosis and comprehension of this sinus @entity715 (author's transl)].

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['convulsive']

entities_list: @entity1269 :: ('MESH:D010291', 'Disease') :: ['sudden left hemiparesis']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficit']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity50 :: ('MESH:D012851', 'Disease') :: ['sagittal sinus thrombosis']

answer: @entity50 :: (MESH:D012851,Disease) :: ['sagittal sinus thrombosis']


abstract: CONTEXT: Research on the perfectionism and emotion regulation strategies in @entity148 has gained increased attention. These have an important implication for formulation of therapies. AIMS: We examined perfectionism, emotion regulation were examined in 30 @entity1 with @entity913 ( @entity913 ) and 30 community @entity1 . SETTINGS AND DESIGN: A cross-sectional design using a clinical and a community control sample was adopted in this exploratory study. MATERIALS AND METHODS: @entity1 were assessed on The Mini-International Neuropsychiatric Interview, Frost's-Multidimensional Perfectionism Scale, Ruminative Response Scale of the response style questionnaire, cognitive emotion regulation questionnaire, Social Interaction @entity148 Scale and the Beck's @entity308 Inventory. STATISTICAL ANALYSIS: Data was analyzed using independents samples t-test and Pearson's Product moment correlations and step-wise linear regression. RESULTS: Individuals with @entity913 had higher perfectionism (mean = 100.30, SD =   17.73, t = 7.29, P < 0.001), rumination (mean = 61.47, SD =   11.96, t = 6.71, P < 0.001) and lower levels of positive reappraisal (mean = 11.53, SD =   3.85, t = 4.90, P < 0.001). Perfectionism was correlated with social @entity148 (r = 0.44, P < 0.05) and rumination (r = 0.43, P < 0.05), but not with @entity308 . Rumination was positively correlated with both social @entity148 (r = 0.513, P < 0.01) and @entity308 (r = 0.485, P < 0.01). Positive reappraisal was negatively correlated with @entity308 (r = -0.396, P < 0.05) and @entity148 (r = -0.335, P < 0.05). Acceptance was found to be significantly correlated only to the reflective pondering subscale of rumination. Parental criticism was a significant predictor of social @entity148 (F = 11.11, P < 0.01) and brooding predicted @entity308 (F = 10.49, P < 0.01). CONCLUSIONS: This study highlights the role of perfectionism as a maintaining factor in @entity913 and the importance of adaptive forms of emotion regulation that need to be addressed in psychological interventions.

title: Perfectionism, emotion regulation and their relationship to negative affect in XXXX with @entity913 .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'Participants']

entities_list: @entity148 :: ('MESH:D001008', 'Disease') :: ['Anxiety', 'anxiety', 'anxiety disorders']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depression']

entities_list: @entity913 :: ('MESH:D010698', 'Disease') :: ['social phobia', 'SP']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: INTRODUCTION: A congenital short QT interval constitutes a new primary electrical abnormality associated with @entity1163 and/or @entity1164 . We report on the initial use of @entity737 ( @entity737 ) therapy in @entity1 with @entity74 and discuss sensing abnormalities and detection issues. METHODS AND RESULTS: In five consecutive @entity1 from two unrelated European families who had structurally normal hearts, excessively shortened QT intervals, and a strong positive family history of @entity1164 , ICDs were placed for primary and secondary prevention. Mean QT intervals were 252 +/- 13 ms (QTc 287 +/- 13 ms). Despite normal sensing behavior during intraoperative and postoperative device testing, 3 of 5 @entity1 experienced inappropriate shock therapies for T wave oversensing 30 +/- 26 days after implantation. Programming lower sensitivities and @entity1547 prevented further inappropriate discharges. CONCLUSION: The @entity12396 constitutes a new clinical entity with an increased risk for @entity1164 . Currently, @entity737 treatment is the only therapeutic option. In @entity1 with @entity1162 , increased risk for inappropriate therapy is inherent due to the detection of short-coupled and prominent T waves. Careful testing of @entity737 function and adaptation of sensing levels and @entity1547 without sacrificing correct @entity943 detection are essential.

title: XXXX and @entity737 treatment: inherent risk for inappropriate shock delivery.

entities_list: @entity1164 :: ('MESH:D016757', 'Disease') :: ['sudden cardiac death']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity12396 :: ('MESH:C566506', 'Disease') :: ['congenital short QT syndrome']

entities_list: @entity737 :: ('MESH:D057873', 'Disease') :: ['ICD', 'implantable cardioverter defibrillator']

entities_list: @entity1547 :: ('MESH:D003731', 'Disease') :: ['decay delays']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['inherited short QT interval']

entities_list: @entity1162 :: ('MESH:D008133', 'Disease') :: ['short QT interval and implanted ICD']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia']

answer: @entity12396 :: (MESH:C566506,Disease) :: ['Congenital short QT syndrome']


abstract: BACKGROUND: Feline @entity298 is a fatal disease of @entity468 caused by infection with @entity25444 (FCoV). For detecting or genotyping of FCoV, some RT-PCR plus nested PCR techniques have been reported previously. However, referring to the whole genome sequences (WGSs) registered at NCBI, there are no detection methods that can tolerate the genetic diversity among FCoV population. In addition, the quasispecies nature of FCoV, which consists of heterogeneous variants, has been also demonstrated; thus, a universal method for heteropopulations of FCoV variants in clinical specimens is desirable. RESULTS: To develop an RT-PCR method for detection and genotyping of FCoV, we performed comparative genome analysis using WGSs of 32 FCoV, 7 CCoV and 5 @entity56094 strains obtained from NCBI. As the PCR target, we focused on the nsp14 coding region, which is highly conserved and phylogenetically informative, and developed a PCR method targeting nsp14 partial sequences. Among 103 ascites, 45 @entity1143 and 214 blood specimens from clinically ill @entity468 , we could detect FCoV in 55 (53.4%), 14 (31.1%) and 19 (8.9%) specimens using the present method. Direct sequencing of PCR products and phylogenetic analysis allowed discrimination between type I- and II-FCoV serotypes. Our nsp14 amino acid sequence typing (nsp14 aa ST) showed that the FCoV clone with sequence type (ST) 42, which was the most predominant genotype of WGS strains, was prevalent in @entity468 in Japan. CONCLUSIONS: Our nsp14 PCR scheme will contribute to virus detection, epidemiology and ecology of FCoV strains.

title: Molecular epidemiological study of XXXX strains in Japan using RT-PCR targeting nsp14 gene.

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusion']

entities_list: @entity25444 :: ('12663', 'Species') :: ['feline coronavirus']

entities_list: @entity468 :: ('9685', 'Species') :: ['domestic cats', 'cats']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['infectious peritonitis']

answer: @entity25444 :: (12663,Species) :: ['feline coronavirus']


abstract: OBJECTIVE: To evaluate the effects of combined treatment for @entity43 and to analyze its prognostic factors. METHODS: Fifty-three @entity1 treated with a three-step combined therapeutic regimen were defined as research arm. The procedures of the three-step combined treatment were as follows: induction of @entity5 remission, sequential chemotherapy and adjuvant immunotherapy. Three hundred and eighteen @entity1 with @entity43 treated with cytoreductive surgery and systemic chemotherapy were retrospectively classified into control arm. RESULTS: The rates of complete response and partial response in the research arm were significantly differed from those in the control arm (90.6%, 5.7% Vs 70.1%, 5.3%, P < 0.01). The 1-, 2- and 3-year survival rates of the research arm and control arm were 97.7%, 89.1%, 83.6% Vs 71.8%, 44.1%, 29.8%, respectively (P < 0.01). The 1-, 2- and 3-year @entity5 -free survival rates of the research arm and control arm were 92.6%, 75.0%, 75.0% Vs 60.3%, 37.8%, 28.6%, respectively (P < 0.01). The 1- and 2-year recurrent rates of the @entity1 in research arm were much lower than that in control arm (7.5%, 25.0% Vs 39.7%, 62.2%, P < 0.01). Age, stage, ascites, differential degree, preoperative chemotherapy (intraperitoneal and/or intravenous chemotherapy), postoperative intraperitoneal chemotherapy and systemic chemotherapy were poor prognostic factors. Initially treated in other @entity5 , large residuals (diameter more than 1cm) and postoperative intraperitoneal chemotherapy were poor @entity5 -free survival prognostic factors. CONCLUSION: Combined therapy including remission induction, consolidation chemotherapy and immunotherapy was able to enhance therapeutic efficacy, decrease the 1- and 2-year recurrent rate and improve the survival of @entity1 with @entity43 .

title: [Combined treatment and prognostic analysis of XXXX ].

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['advanced epithelial ovarian carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'hospital, bilateral tumors']

answer: @entity43 :: (MESH:D010051,Disease) :: ['advanced epithelial ovarian carcinoma']


abstract: OBJECTIVE: Neonatal @entity2806 ( @entity2806 ) still carries a high burden by its mortality and long-term @entity16 in survivors. Apart from @entity2332 , there is no acknowledged therapy for @entity2806 , reflecting the lack of mechanistic understanding of its pathophysiology. (Macro)autophagy, a physiological intracellular process of lysosomal degradation, has been proposed to be excessively activated in excitotoxic conditions such as @entity2806 . The present study examines whether neuronal autophagy in the thalamus of asphyxiated @entity1 newborns or P7 @entity35 is enhanced and related to @entity528 processes. METHODS: Neuronal autophagy and cell death were evaluated in the thalamus (frequently injured in severe @entity2806 ) of both @entity1 newborns who died after severe @entity2806 (n   =   5) and P7 @entity519 - @entity63 @entity35 ( @entity579 -Vannuci model). Autophagic (LC3, @entity10407 ), lysosomal ( @entity3220 , cathepsins), and cell death (TUNEL, @entity522 ) markers were studied by immunohistochemistry in @entity1 and @entity35 brain sections, and by additional methods in @entity35 (immunoblotting, histochemistry, and electron microscopy). RESULTS: Following severe perinatal @entity1763 in both @entity1 and @entity35 , thalamic neurons displayed up to 10-fold (p   <   0.001) higher numbers of autophagosomes and lysosomes, implying an enhanced autophagic flux. The highly autophagic neurons presented strong features of apoptosis. These findings were confirmed and elucidated in more detail in @entity35 . INTERPRETATION: These results show for the first time that autophagy is enhanced in severe @entity2806 in dying thalamic neurons of @entity1 newborns, as in @entity35 . Experimental neuroprotective strategies targeting autophagy could thus be a promising lead to follow for the development of future therapeutic approaches. Ann Neurol 2014;76:695-711.

title: Dying neurons in thalamus of asphyxiated term newborns and XXXX are autophagic.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'humans']

entities_list: @entity2806 :: ('MESH:D002545', 'Disease') :: ['hypoxic-ischemic encephalopathy', 'HIE']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological morbidity']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal death']

entities_list: @entity2332 :: ('MESH:D007035', 'Disease') :: ['hypothermia']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: BACKGROUND: @entity195 ( @entity195 ) is associated with considerable costs and has a significant impact on health and social care systems. OBJECTIVE: This study assessed whether baseline comorbidities present in 2,594 @entity1 with @entity195 participating in two semagacestat @entity23 ( @entity23 ) would significantly impact overall costs. METHODS: Resource utilization was captured using the Resource Utilization in @entity303 Scale-Lite. Comorbidities and concomitant medications were tabulated via @entity1 and caregiver reports. Only baseline data were analyzed. Direct and indirect costs per month were calculated per @entity1 . The relationship between cost and explanatory variables was explored in a regression model. RESULTS: The baseline monthly cost of care in this RCT population was   1,147      2,483, with informal care costs accounting for 75  % of costs. Gender, age, and functional status were significant predictors of costs (p   <=  0.0001). The cost ratio was not impacted when the number of comorbidities was added to the model (cost ratio  =  0.95; 95  % CI 0.91-0.99) or when combined with the number of concomitant medications (cost ratio  =  0.97; 95  % CI 0.95-1.00). Inconsistent findings related to the impact of individual comorbidities on costs were noted in sensitivity analyses. CONCLUSIONS: The number of comorbidities, alone or when combined with concomitant medications, did not impact baseline costs of care, perhaps because @entity23 often enroll less severely ill and more medically stable @entity1 . However, higher costs were consistently associated with greater functional impairment similar to non-RCT databases. Supplemental sources (e.g., claims databases) are likely needed to better estimate the effects of disease and treatment on costs of illness captured in @entity23 for @entity195 .

title: Methodological challenges in assessing the impact of comorbidities on costs in XXXX clinical trials.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity23 :: ('MESH:D007174', 'Disease') :: ['RCTs', 'randomized placebo-controlled trials']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['Dementia']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"]

answer: @entity195 :: (MESH:D000544,Disease) :: ['Alzheimer's disease']


abstract: STUDY OBJECTIVE: The optimal timing to begin @entity64 prevention therapy in @entity1 being discharged from an @entity341 ( @entity341 ) with @entity955 is not known. We determined whether eligible @entity1 who were provided with an @entity341 prescription for oral anticoagulation had better rates of long-term anticoagulation use than eligible @entity1 who were referred to their primary care provider for further care. METHODS: As part of a historical cohort study, in this planned substudy we abstracted data from @entity1 charts with a primary diagnosis of @entity955 from 24 EDs between April 1, 2008, and March 31, 2009. In the current study, discharged @entity1 aged 65 years and older who had a CHADS2 score greater than or equal to 2 and a HAS-BLED score less than 3, with no history of falls and who were not receiving oral anticoagulation when they presented to the @entity341 , were included. We compared the frequency of @entity1229 use at 6 months and 1 year after @entity341 discharge for @entity1 who were given a prescription for @entity1229 before they left the @entity341 to those who were not. RESULTS: Among 137 qualifying @entity1 , 33 (24.1%) were provided with a @entity1229 prescription before discharge from the @entity341 . At 6 months, 25 of the 33 were still receiving @entity1229 , compared with 34 of 104 among the @entity1 who were not given an @entity341 prescription (absolute difference, 43.1%; 95% confidence interval [CI] 23.8 to 57.2). At 1 year, 75.8% versus 35.6% (absolute difference, 40.2%; 95% CI 20.9 to 54.4) were receiving @entity1229 , respectively. Among the @entity1 who filled a prescription for @entity1229 , the mean number of days from @entity341 discharge until a @entity1229 prescription was filled was 6.0 (SD 21.3) for @entity1 who were provided with an @entity341 prescription compared with 205 (SD 377) for those who were not. CONCLUSION: Among @entity341 @entity1 who met criteria for guideline-recommended use of @entity64 prevention therapy, those who received an initial prescription in the @entity341 had a higher frequency of long-term @entity1229 use than those for whom the decision to initiate therapy was referred to another care provider.

title: The Long-Term Use of @entity1229 Among @entity955 XXXX Discharged From an Emergency Department With a @entity1229 Prescription.

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['emergency department', 'ED']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: @entity907 is the most common cause of @entity1163 in @entity1 who present in outpatient clinics. @entity135 ( @entity135 ) has been widely used to diagnose @entity907 . However, the @entity135 does not always produce a positive response in @entity1 with suspected @entity907 . The aim of the present study was to assess the clinical history and characteristics of @entity1 with suspected @entity907 or @entity1163 who undertook @entity135 , and to identify prognostic factors of a positive @entity135 response. During the first phase of @entity135 , @entity1 were tilted to a 70-degree angle for 30 minutes. If the first phase produced a negative response, the second phase was subsequently performed involving intravenous @entity3044 administration. Of 711 @entity1 , 423 (59.5%) @entity1 showed a positive @entity135 response. In contrast to previous studies, this study showed that the vasodepressive type (76.6%) was the most common pattern of positive response, and that the rate of positive response during the first phase was low (7.1%). By multivariate analysis, the occurrence of junctional rhythm was found to be a predictor of an impending positive response in @entity135 (P < 0.001). The shorter time interval between the last episode and @entity135 was also a predictor of positive response (P = 0.0015). Younger age (P = 0.0003) and a history of @entity130 during a @entity1163 (P = 0.019) were found to be associated with a positive response in the first phase of @entity135 .

title: Predictors of positive head-up tilt test in @entity1 with suspected @entity907 or XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['Head-up tilt test', 'HUT']

entities_list: @entity907 :: ('MESH:D019462', 'Disease') :: ['neurocardiogenic syncope', 'Neurocardiogenic syncope']

entities_list: @entity1163 :: ('MESH:D013575', 'Disease') :: ['syncope', 'presyncope', 'syncopal episode']

entities_list: @entity3044 :: ('MESH:D007545', 'Chemical') :: ['isoproterenol']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['physical injury']

answer: @entity1163 :: (MESH:D013575,Disease) :: ['presyncope']


abstract: UNASSIGNED: This report concerns the effect of @entity1457 on host-pathogen interaction in Galleria mellonella infected with @entity11137 . We show enhanced activity against Gram-positive bacteria in the hemolymph of larvae pre-exposed to @entity1457 before @entity281 with @entity11137 . @entity1457 influenced the protein pattern in the hemolymph of infected larvae: more peptides with a molecular weight below 10 kDa were detected in comparison with nonshocked animals. Additionally, we noticed that the amount of apolipophorin III (apoLp-III) in the hemolymph decreased transiently following @entity281 , which was considerably higher in larvae pre-exposed to @entity1457 . On the other hand, its expression in the fat body showed a consequent @entity281 -induced decline, observed equally in shocked and nonshocked animals. This suggests that the amount of apoLp-III in the hemolymph of G. mellonella larvae is regulated at multiple levels. We also report that this protein is more resistant to degradation in the hemolymph of larvae pre-exposed to @entity1457 in comparison to nonshocked larvae. Two-dimensional analysis revealed the presence of three isoforms of apoLp-III, all susceptible to proteolytic degradation. However, one of them was the most abundant, both in the protease-treated and untreated hemolymph. Taking into consideration that, in general, apoLp-III has a stimulative effect on different immune-related hemolymph proteins and peptides, the reported findings bring us closer to understanding the effect of @entity1457 on the resistance of G. mellonella to @entity281 .

title: CHANGES IN THE HEMOLYMPH PROTEIN PROFILES IN Galleria mellonella INFECTED WITH XXXX INVOLVE APOLIPOPHORIN III. THE EFFECT OF HEAT SHOCK.

entities_list: @entity1457 :: ('MESH:D012769', 'Disease') :: ['Heat shock', 'heat shock']

entities_list: @entity11137 :: ('1428', 'Species') :: ['Bacillus thuringiensis', 'B. thuringiensis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity11137 :: (1428,Species) :: ['Bacillus thuringiensis']


abstract: AIMS: To determine the age-specific prevalence rates of different types of @entity322 in @entity1 with urinary symptoms using urodynamic studies (UDS). METHODS: One thousand five hundred @entity1 with urinary symptoms who underwent UDS in our department from January 1997 through December 1999 were enrolled. A detailed history, physical examination, and data of multi-channel UDS including uroflowmetry, filling and voiding cystometry, stress urethral pressure profile, and 20-minute pad test were obtained for each @entity1 . The urodynamic findings of each @entity1 were analyzed and correlated with age in decades. RESULTS: Of 1,500 @entity1 , 329 were excluded from analysis because they had undergone anti- @entity322 surgery (n=27), had undergone treatment for cervical @entity5 (n=147), or were being followed-up after medication (n=155). Of the remaining 1,171 @entity1 , 656 (56%) had genuine stress @entity322 (GSI), 68 (5.8%) had @entity1344 ( @entity1344 ), 187 (16%) had mixed GSI/ @entity1344 , 245 (20.9%) had either @entity409 without concomitant @entity322 , and 15 (1.3%) had normal urodynamic findings. The 41-50- and 51-60-year age groups had the highest prevalence rates of @entity322 , accounting for 31% and 28% of GSI cases, 35% and 25% of @entity1344 cases, and 40% and 27% of mixed GSI/ @entity1344 cases, respectively. The prevalence of GSI and mixed GSI/ @entity1344 increased consistently with age, but the prevalence of @entity1344 decreased after age 66. Thus, the prevalence rates of GSI, @entity1344 , and mixed GSI/ @entity1344 were 56%, 5.8%, and 16%, respectively, in @entity1 with urinary symptoms. CONCLUSIONS: Female @entity322 had a biogenic peak prevalence in the 41-50-year and 51-60-year age groups.

title: Urodynamically age-specific prevalence of @entity322 in XXXX with urinary symptoms.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity322 :: ('MESH:D014549', 'Disease') :: ['urinary incontinence', 'incontinence']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['voiding or storing dysfunction']

entities_list: @entity1344 :: ('MESH:D043171', 'Disease') :: ['DI', 'detrusor instability']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: BACKGROUND: @entity57993 , a @entity3857 extracted from @entity9052 , inhibits angiogenesis. The combination of low-dose chemotherapy and anti-angiogenic inhibitors suppresses growth of experimental @entity5 more effectively than conventional therapy or anti-angiogenic agent alone. The present study was designed to evaluate the efficacy of low-dose @entity136 combined with @entity57993 on angiogenesis and growth of @entity2 in @entity19 . METHODS: C57L/6 @entity19 implanted with @entity2 were randomized into the control, @entity57993 , @entity136 and combination group. The quality of life and survival of @entity19 were recorded. @entity5 volume, inhibitive rate and @entity39 rate were estimated. Necrosis of @entity5 and signals of blood flow as well as dynamic parameters of arterial blood flow in @entity5 such as peak systolic velocity (PSV) and resistive index (RI) were detected by color Doppler ultrasound. In addition, expression of @entity1611 ( @entity1611 ) and @entity5231 were observed by immunohistochemstry, and microvessel density (MVD) of the @entity5 tissues was assessed by @entity5231 immunohistochemical analysis. RESULTS: Quality of life of @entity19 in the @entity57993 and combination group were better than in the control and @entity136 group. Combined therapy with @entity57993 and @entity136 not only enhanced efficacy on suppression of @entity5 growth and prolongation of the survival, but also increased @entity39 rate of @entity5 significantly. In addition, the combination treatment could obviously decrease @entity1611 expression and MVD as well as signals of blood flow and PSV in @entity5 . CONCLUSION: @entity57993 combined with @entity136 may significantly inhibit angiogenesis and growth of @entity2 and improve survival and quality of life of @entity5 -bearing @entity19 . The combination of chemotherapy and anti-angiogenic drugs may be an innovative and promising therapeutic strategy in the experimental treatment of @entity1 @entity2 .

title: Inhibitory effect of XXXX combined with @entity136 on angiogenesis and growth of @entity2 in @entity19 .

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity57993 :: ('MESH:C097367', 'Chemical') :: ['Ginsenoside Rg3', 'ginsenoside Rg3']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'tumors']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['established Lewis lung carcinoma', 'Lewis lung carcinoma', 'lung cancer']

entities_list: @entity1611 :: ('22339(Tax:10090)', 'Gene') :: ['vascular endothelial cell growth factor', 'VEGF']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

answer: @entity57993 :: (MESH:C097367,Chemical) :: ['ginsenoside Rg3']


abstract: @entity19 plasmacytomas (MPCs) induced by pristane oil, or by a combination of pristane @entity778 , carry one of two chromosomal translocations. The typical 12; 15 translocation leads to the juxtaposition of c-myc and immunoglobulin heavy-chain sequences, whereas the 6; 15 translocation links the kappa light-chain locus with the @entity19091 (plasmacytoma variant translocation) locus, located at least 75kb 3' of c-myc [Cory, S., Graham, M., Webb, E., Corcoran, L. _ Adams, J. (1985). EMBO J., 4, 675-681]. Unlike the @entity1 @entity2109 -associated translocation, the lambda/myc juxtaposed variant translocation has not been found previously in MPCs. Using unconventional MPC induction systems in which the @entity5 precursor cell was induced to proliferate in a secondary host, we have recently identified a 15; 16 translocation in six of the derived MPCs [Wiener, F., Silva, S., Sugiyama, H., Babonits, M. _ Klein, G. (1990). Genes Chromosomes Cancer, 2, 36-43]. Chromosome 16 harbors the lambda light-chain gene. To explore whether the 15; 16 translocation represents the lambda/myc juxtaposition, we have mapped the breakpoints on chromosomes 15 and 16 by pulsed-field gel electrophoresis (PFGE). The @entity19091 region was mapped to approximately 220 kb 3' of c-myc. The breakpoint on chromosome 15 in ABPC-Ch-163-10, one of the six 15; 16 translocation-carrying MPCs, was situated approximately 80 kb 3' of c-myc and 140 kb 5' of pvt-1b, the major breakpoint cluster region of the previously analysed 6; 15 variant MPCs. The breakpoint on chromosome 16 was found to cut between the V1 and C3 regions of the lambda locus. Co-migration experiments showed that the C3 and the myc gene were juxtaposed head to tail on the 15; 16 translocation chromosome. On the reciprocal product V1 was juxtaposed to @entity19091 .

title: A new variant 15; 16 translocation in XXXX plasmacytoma leads to the juxtaposition of c-myc and immunoglobulin lambda.

entities_list: @entity778 :: ('MESH:D015658', 'Disease') :: ['oil and Abelson virus']

entities_list: @entity2109 :: ('MESH:D002051', 'Disease') :: ["Burkitt's lymphoma"]

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: UNASSIGNED: 1052 Background: Bevacizumab with chemotherapy has shown improvement in progression-free survival (PFS) in @entity0 @entity1 (pts) (Miller 2007; Miles 2008; Brufsky 2009; Robert, et al 2009). We examined the efficacy/safety of combining B with G as first-line therapy in @entity3907 -pretreated @entity0 pts. METHODS: This US, multicenter, single arm, open-label trial enrolled 52 pts. Eligibility criteria included: @entity1722 -negative, recurrent or @entity0 , performance status (PS) 0-1, and prior @entity3907 as neoadjuvant and/or adjuvant therapy with a >12 month disease-free interval. Pts received G 2500 mg/m(2) plus B 10 mg/kg on day (d) 1, both in 14-d cycles. Pts were treated until @entity74 ( @entity74 ), complete response (CR), or intolerable @entity137 . The primary endpoint was PFS; secondary endpoints were overall response rate (ORR), 1-year survival rate, and safety. @entity137 were graded according to NCI CTC v 3.0. RESULTS: Between March 2008 and January 2010, 52 @entity1 were enrolled and treated. Median age 55 (range 28-78); 30 ER+/PR+; 19 ER-/PR-/ @entity1722 -; PS 0/1, 28/24 pts. Five pts experienced >= 1 serious drug-related adverse event (AE). Ten pts discontinued due to AEs; 5 pts were hospitalized for drug-related AEs. Drug-related treatment-emergent AEs (TEAEs) of all grades present in >20% of pts were: nausea (51.9%), @entity1295 (46.2%), @entity448 (21.2%), @entity1398 (23.1%), and @entity417 (21.2%). Grade (Gr) 3 drug-related TEAEs occurring in >= 2% of pts were @entity1398 (13.5%), @entity1431 (7.7%), @entity101 (7.7%), @entity882 (3.8%), and @entity417 (3.8%). Two pts experienced Gr 4 TEAEs: 1 pt, @entity1381 + @entity810 + @entity1431 ; 1 pt, @entity1151 . There were no deaths from study drug @entity137 . The median number of cycles received was 8 (range 1-30). Median dose intensities were: G, 96.8% and B, 97.6%. The ORR was 21.4% (0 CR; 9 partial responses). Nineteen (45.2%) pts had stable disease. Median PFS is 4.8 months (95% confidence interval: 3.4-7.2). The 1-year overall survival rate is 67.1%. CONCLUSIONS: Therapy with G+B is well tolerated with demonstrated activity in this poor prognosis group. Final efficacy data will be presented at the meeting.

title: Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in @entity3907 -pretreated, @entity1722 -negative, locally recurrent or @entity0 ( XXXX ).

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicities']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progressive disease']

entities_list: @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia']

entities_list: @entity1381 :: ('MESH:D006463', 'Disease') :: ['hemolytic uremic syndrome']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['acute renal failure']

answer: @entity0 :: (MESH:D001943,Disease) :: ['MBC']


abstract: UNASSIGNED: 24 Background: High-level evidence has demonstrated that earlier palliative care (PC) improves outcomes for @entity1 with advanced @entity5 , but a limited PC workforce and lack of outpatient resources remain barriers to access. In 2010, a productive intersection of oncologist-driven response to new evidence and Providence @entity5 Center assessment of end of life care quality metrics resulted in funding of an outpatient Oncology Palliative Care Program (OPCP). An initial NP/LCSW team began concurrent PC for advanced lung and @entity788 @entity1 in a specialty clinic setting in 2011. Scope of service was expanded to include other diagnoses in 2012. Early positive outcomes and oncology team feedback led to @entity5 Center funding of a second PC team at a separate service site in August 2013; the OPCP simultaneously transitioned to an embedded care model. METHODS: Retrospective chart review of @entity1 deaths for all Providence Medical Group (PMG) @entity5 Center @entity1 not served by OPCP; review of OPCP referral data since adoption of embedded model (n= 177). Quarterly quality metrics included: % @entity1 on hospice at time of @entity204 ; % @entity1 with evidence of an @entity1442 ( @entity1442 ) discussion documented in the electronic medical record (EMR); and % @entity1 receiving chemotherapy at end of life. RESULTS: A significant improvement in the % PMG oncology @entity1 with evidence of an @entity1442 discussion occurred from 2010 baseline of 59.5% to 74.5% in 2013 (z=4.03, p<.001). In addition, % @entity1 receiving chemotherapy in the last 14 days of life decreased from 5.9% in 2010 to 2.7% in 2013 (z=1.9; p<.05). For @entity1 referred to the OPCP, referral diagnoses evolved from 100% lung and @entity788 to 34 % lung and @entity788 and 66 % other diagnoses. CONCLUSIONS: Incremental growth of the Providence OPCP has demonstrated successful expansion to diagnoses beyond @entity5 . Improvement in end of life care quality metrics for oncology @entity1 not served by the program (perhaps by elevating "generalist" PC skills) may be an additional benefit and value of a highly visible embedded PC team in a community @entity5 center, particularly with respect to modeling best practice of early goals of care discussions and @entity1442 .

title: Extended impact of an embedded palliative care program in a community XXXX center.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreas carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer', 'end stage lung carcinoma', 'Cancer']

entities_list: @entity1442 :: ('MESH:D020178', 'Disease') :: ['Advance Care Planning', 'ACP']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: BACKGROUND AND AIM: Endoscopic resection is widely adopted for early @entity14 . Most studies examining the effectiveness of endoscopic treatment of early @entity14 are from Japan, and little is known about the success of this treatment in other areas of the world. The authors performed this study to investigate the effectiveness of endoscopic treatment of early @entity14 . METHODS: The medical records of @entity1 with histologically proven early @entity14 and who were treated by endoscopic resection between January 1985 and December 2000 were reviewed retrospectively. Information regarding the demographic data of @entity1 , clinicopathological characteristics of the @entity5 , and follow-up events were recorded and analyzed. RESULTS: Altogether 91 @entity1 , including 73 with @entity1697 and 18 with @entity3 , were enrolled. Nineteen @entity1 (eight with @entity1697 and 11 with @entity3 ) underwent subsequent surgical colectomy. @entity5 , and those with sessile or flat depressed morphology, and @entity3 were more difficult to remove completely through endoscopic resection alone. Five @entity1 had local recurrent @entity5 , occurring between 4 and 12 months after endoscopic resection, and were treated surgically. Furthermore, two @entity1 died of unrelated diseases, one at 1 month and one at 3 years after treatment. All the other @entity1 were well after an average follow-up interval of 40.9 months (range 18-189 months). CONCLUSIONS: Endoscopic resection safely and effectively removed most early @entity14 . Careful histological examinations of resected specimens to determine the indications of subsequent surgical colectomy, and close post-treatment surveillance would improve the outcome and life quality for these @entity1 .

title: Clinical outcome of endoscopically removed early XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1697 :: ('MESH:D009062', 'Disease') :: ['mucosal cancers']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Larger tumors', 'tumors']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['deep submucosal invasion', 'submucosal invasive cancers']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancers', 'colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: PURPOSE: Psychological responses to @entity5 are widely believed to affect survival. We investigated associations between hope, optimism, @entity148 , @entity308 , health utility and survival in @entity1 starting first-line chemotherapy for metastatic @entity14 . METHODS: Four hundred twenty-nine subjects with metastatic @entity14 in a randomised controlled trial of chemotherapy completed baseline questionnaires assessing the following: hopefulness, optimism, @entity148 and @entity308 and health utility. Hazard ratios (HRs) and P values were calculated with Cox models for @entity1349 ( @entity1349 ) and progression-free survival (PFS) in univariable and multivariable analyses. RESULTS: Median follow-up was 31  months. Univariable analyses showed that @entity1349 was associated negatively with @entity308 (HR 2.04, P  <  0.001) and positively with health utility (HR 0.56, P  <  0.001) and hopefulness (HR 0.75, P  =  0.013). In multivariable analysis, @entity1349 was also associated negatively with @entity308 (HR 1.72, P  <  0.001) and positively with health utility (HR 0.73, P  =  0.014), but not with optimism, @entity148 or hopefulness. PFS was not associated with hope, optimism, @entity148 or @entity308 in any analyses. CONCLUSIONS: @entity308 and health utility, but not optimism, hope or @entity148 , were associated with survival after controlling for known prognostic factors in @entity1 with advanced @entity14 . Further research is required to understand the nature of the relationship between @entity308 and survival. If a causal mechanism is identified, this may lead to interventional possibilities.

title: Hope, optimism and survival in a randomised trial of chemotherapy for metastatic XXXX .

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depression']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: BACKGROUND: Measurement of @entity1904 (PCT) has been studied for several years in @entity166 . Some studies have focused on @entity497 ( @entity497 ) but only one was conducted in critically ill @entity1 hospitalized in an @entity1213 ( @entity1213 ). @entity1 AND METHODS: To determine the diagnostic and prognostic role of PCT in @entity1 admitted in an @entity1213 for severe @entity497 , 110 @entity1 hospitalized in our unit were prospectively studied. Within 48 hours following @entity1213 admission, PCT serum level was measured with a quantitative method above a threshold value of 0.5 ng/ml. RESULTS: Initially focusing on the diagnostic value of PCT, 20% of the @entity1 had a serum PCT level <0.5 ng/ml, 30% between 0.5 ng/ml and 2 ng/ml, and 50%>/=2 ng/ml. Serum PCT level was higher in microbiologically documented @entity497 (median=4.9 ng/ml vs 1.5 ng/ml if no bacteria were found; p=0.001), but was not predictive of any specific bacterial agent. Concerning the prognostic value, the serum PCT level was higher for bacteremic @entity1 and/or @entity326 @entity1 (4.9 ng/ml vs 1.5 ng/ml; p=0.0003). Moreover, PCT levels were increased in @entity1 who developed, during their @entity1213 stay, @entity281 ( @entity326 , acute @entity649 and @entity5642 ). Finally, the initial PCT level was significantly higher in @entity1 who died during the @entity1213 stay (5.6 ng/ml vs 1.5 ng/ml; p<0.0001). Such a relationship was not found with @entity1851 (CRP). CONCLUSION: In @entity1213 @entity1 admitted for severe @entity497 , initial PCT values could be an interesting predictor for complications and mortality.

title: Diagnostic and prognostic values of admission procalcitonin levels in XXXX in an @entity1213 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity326 :: ('MESH:D012772', 'Disease') :: ['septic shock, multiorgan dysfunction', 'septic shock']

entities_list: @entity1904 :: ('MESH:C029100', 'Chemical') :: ['procalcitonin']

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['respiratory distress syndrome']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection-related complications']

entities_list: @entity5642 :: ('MESH:D004211', 'Disease') :: ['disseminated intravascular coagulation']

entities_list: @entity497 :: ('MESH:D003147', 'Disease') :: ['CAP', 'community-acquired pneumonia']

entities_list: @entity1213 :: ('MESH:D012555', 'Disease') :: ['intensive care unit', 'ICU']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious diseases']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']

answer: @entity497 :: (MESH:D003147,Disease) :: ['community-acquired pneumonia']


abstract: OBJECTIVE: To evaluate the results of negative-pressure wound therapy (NPWT) in the treatment of surgical spinal site @entity281 . MATERIALS AND METHODS: The use of NPWT in @entity86 after dorsal spinal surgery (transforaminal lumbar interbody fusion plus posterior instrumentation) was studied retrospectively. From February 2011 to January 2012, six @entity1 (females) out of 317 (209 females; 108 males) were readmitted to our clinic with surgical site @entity281 on postoperative day 14 (range 9-19) and were treated with debridement, NPWT, and antibiotics. We evaluated the clinical and laboratory data, including the ability to retain the spinal hardware and recurrent @entity281 . RESULTS: The incidence of @entity86 was six (1.89%) @entity1 (females) out of 317 @entity1 (209 females; 108 males) at 1 year. All @entity1 completed their wound NPWT regimen successfully. An average of 5.1 (range 3-8) irrigation and debridement sessions was performed before definitive wound closure. The mean follow-up period was 13 (range 12-16) months. No @entity1 had a @entity281 requiring partial or total hardware removal. The hospital stay infection parameters normalized within an average of 4.6 weeks. CONCLUSION: The study illustrates the usefulness of NPWT as an effective adjuvant treatment option for managing complicated deep spinal surgical wound @entity281 .

title: Wound management with vacuum-assisted closure in XXXX after surgery for spinal stenosis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['persistent infection', 'infections']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative infections', 'deep postoperative surgical site infection']

answer: @entity86 :: (MESH:D019106,Disease) :: ['postoperative infections']


abstract: BACKGROUND: @entity810 ( @entity810 ) is a serious and common problem that is associated with high mortality. Currently nearly all efforts at improving outcomes in @entity810 have been focused on secondary care. We now know that a large number of @entity1 most likely develop the condition in primary care. To our knowledge there has been no previous attempts to approach this topic from the primary care perspective. AIM: To test the utility of novel informatics software to identify @entity1 with @entity810 in the community. SETTING AND METHOD: We carried out a retrospective audit of @entity1 in one urban practice in Leicestershire using novel informatics software. The audit data was run on two occasions, once for high-risk @entity1 between 4th July 2010 through until 30th September 2013, and once for low risk @entity1 for the period of 27th October 2011 through until 21st January 2014. RESULTS: During the period of the data collection the average practice list size was 12,420, with 235 and 19 @entity810 episodes in the high and low risk groups respectively. The annual @entity810 incidence was 27.9/1000 in the high-risk group, 1.22/1000 in the low risk group, and 10.6/1000 overall. The most common associated factor was sepsis in 170 @entity1 , followed by @entity2700 in 54 @entity1 . CONCLUSION: We have shown it is possible to identify @entity1 with @entity810 in the community using informatics software. Our data suggests that @entity810 in the community is much more common than previously thought and demonstrates the need to better understand this condition from the primary care perspective.

title: Identifying XXXX in the community-a novel informatics approach.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2700 :: ('MESH:D003681', 'Disease') :: ['dehydration']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['AKI', 'Acute kidney injury']

answer: @entity810 :: (MESH:D058186,Disease) :: ['acute kidney injury']


abstract: @entity972 (K) channels have a key role in the regulation of neuronal excitability. Over a hundred different subunits encoding distinct K channel subtypes have been identified so far. A major challenge is to relate these many different channel subunits to the functional K currents observed in native neurons. In this review, we have concentrated on cerebellar granule neurons (CGNs). We have considered each of the three principal super families of K channels in turn, namely, the six transmembrane domain, voltage-gated super family, the two transmembrane domain, inward-rectifier super family and the four transmembrane domain, leak channel super family. For each super family, we have identified the subunits that are expressed in CGNs and related the properties of these expressed channel subunits to the functional currents seen in electrophysiological recordings from these neurons. In some cases, there are strong molecular candidates for proteins underlying observed currents. In other cases the correlation is less clear. We show that at least 26 @entity972 channel alpha subunits are moderately or strongly expressed in CGNs. Nevertheless, a good empirical model of @entity10399 function has been obtained with just six distinct K conductances. The transient KA current in CGNs, seems due to expression of @entity13450 channels or @entity13450 /4.3 heteromers, while the KCa current is due to expression of large-conductance slo channels. The G-protein activated @entity9371 current is probably due to heteromeric expression of @entity2486 and @entity21764 . Perhaps @entity19378 subunits underlie the @entity9371 current when it is constitutively active. The leak conductance can be attributed to @entity43113 and or @entity9902 channels. With less certainty, the IK-slow current may be due to expression of one or more members of the KCNQ or EAG family. Lastly, the delayed-rectifier Kv current has as many as six different potential contributors from the extensive Kv family of alpha subunits. Since many of these subunits are highly regulated by neurotransmitters, physiological regulators and, often, auxiliary subunits, the resulting electrical properties of CGNs may be highly dynamic and subject to constant fine-tuning.

title: What are the roles of the many different types of XXXX channel expressed in cerebellar granule cells?

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium', 'Potassium']

answer: @entity972 :: (MESH:D011188,Chemical) :: ['potassium']


abstract: UNASSIGNED: Endoscopic submucosal dissection (ESD) enables wider @entity5 resection compared with endoscopic mucosal resection and en bloc resection of superficial @entity418 . However, ESD may cause difficult-to-treat stricture of the esophagus, and therefore, prediction of and measures against postoperative esophageal stricture are critical. The aim of this study was to evaluate the effect of ESD on superficial @entity418 and identify risk factors associated with esophageal stricture after ESD.This study included 165 lesions in 120 @entity1 with superficial @entity418 , including @entity5 and @entity5 , who underwent ESD from 2009 to 2013.The complete resection rate of superficial @entity418 by ESD was 90.9%. After ESD, 22 subjects (18.3%) had symptomatic esophageal stricture, 12 (10.0%) had aspiration pneumonia of grade 2, and 7 (5.8%) had mediastinal emphysema of grade 2. Comparison of the 22 subjects with stricture with the 98 subjects without stricture showed significant differences in the rate of resection of >75% of the esophageal circumference, rate of whole circumference resection, and the required time for resection. The @entity5 size and the size of the resected tissue sample also differed between the 2 groups. The groups did not differ in age, sex, @entity167 intake, and smoking; location, macroscopic, and histological @entity5 findings; @entity662 ; or use of anticoagulants for comorbidities. In multivariate analysis, @entity5 size and whole circumference resection were independent risk factors for stricture. Furthermore, in 45 subjects with resection of >75% of the esophageal circumference, whole resection of the esophagus was the only independent risk factor for stricture.This study suggests that ESD has a strong therapeutic effect on superficial @entity418 ; however, a greater extent of resection of the esophagus increases the risk of postoperative esophageal stricture. Preventive measures against development of @entity86 require further study.

title: Effect of Endoscopic Submucosal Dissection for Superficial Esophageal Neoplasms and Risk Factors for XXXX .

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'neoplasia']

entities_list: @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol']

entities_list: @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal neoplasms']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative stricture']

answer: @entity86 :: (MESH:D019106,Disease) :: ['Postoperative Stricture']


abstract: UNASSIGNED: Psoriasis, a @entity272 characterized by impaired epidermal differentiation, is regularly treated by systemic @entity1499 ( @entity1500 ), an effective cytotoxic drug but with numerous side effects. The aim of this work was to design topical @entity1500 loaded niosomes for management of @entity1569 to avoid systemic @entity137 . To achieve this goal, @entity1500 niosomes were prepared by thin film hydration technique. A Box-Behnken (BB) design, using Design-Expert(  ) software, was employed to statistically optimize formulation variables. Three independent variables were evaluated: @entity1500 concentration in hydration medium (X1), total weight of niosomal components (X2) and surfactant: @entity165 ratio (X3). The encapsulation efficiency percent (Y1: EE%) and particle size (Y2: PS) were selected as dependent variables. The optimal formulation (F12) displayed spherical morphology under transmission electron microscopy (TEM), optimum particle size of 1375.00nm and high EE% of 78.66%. In-vivo skin deposition study showed that the highest value of percentage drug deposited (22.45%) and AUC0-10 (1.15mg.h/cm(2)) of @entity1500 from niosomes were significantly greater than that of drug solution (13.87% and 0.49mg.h/cm(2), respectively). Moreover, in-vivo histopathological studies confirmed safety of topically applied niosomes. Concisely, the results showed that targeted @entity1500 delivery might be achieved using topically applied niosomes for enhanced treatment of @entity1569 .

title: Design and optimization of topical @entity1499 loaded niosomes for enhanced management of XXXX : Application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin disorder']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity1569 :: (MESH:D011565,Disease) :: ['psoriasis']


abstract: AIM OF THE STUDY: Due to the emergence of new therapeutic opportunities in the second-line treatment of @entity1358 , the choice of the appropriate medication requires consideration. Making the selection one should take into account the likelihood of response, the probability of @entity137 , properties of the drug and the clinical characteristics of the @entity1 . Aim of the work was to confirm antitumor efficacy of @entity16231 in @entity1 with metastatic clear-cell @entity1358 in the second line treatment remaining under the care of our institution. The primary objective was to determine antitumor activity, secondary - to evaluate progression free survival, safety of the treatment and to analyse clinical characteristics of treated population. RESULTS: Treatment records of 27 @entity1 (9 females, 18 males) treated from October 2014 to the present (July 2016) were reviewed. The median duration of treatment which corresponds to the time to disease progression in observed population was 6 months (range: under 1 month - 16 months). 1 @entity1 (3.7%) had got objective response (PR, partial remission). Clinical benefit rate (PR + SD (stable disease) was 66%. 9 @entity1 (33.33%) experienced treatment @entity137 only in the first degree of CTCAE (common @entity137 criteria for adverse events), 11 @entity1 (40.74%) presented the second degree @entity137 and 5 @entity1 (18.5%) - third degree. The most commonly reported treatment related adverse events were @entity294 (47%), @entity1295 (26%), @entity8566 (26%), deterioration of blood pressure control (22.2%), @entity409 tests (18.5%), @entity33 (11.1%). We observed 3 cases of unacceptable @entity137 . CONCLUSIONS: @entity16231 confirms its effectiveness also in situation outside clinical trials, however, it is characterized by significant @entity137 . Therefore, qualification for treatment should take into account the clinical @entity1 characteristics. Effective diagnosis and treatment of side effects and dose optimization are the key skills of the attending physician.

title: XXXX in @entity1358 : single center experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity16231 :: ('MESH:C503983', 'Chemical') :: ['Axitinib', 'axitinib']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['abnormal liver function']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal-cell carcinoma', 'metastatic renal cell carcinoma']

entities_list: @entity8566 :: ('MESH:D060831', 'Disease') :: ['hand-foot syndrome']

answer: @entity16231 :: (MESH:C503983,Chemical) :: ['Axitinib']


abstract: BACKGROUND: Arrhythmokinesis, the variability in repetitive movements, is a fundamental feature of @entity191 ( @entity191 ). We hypothesized that unimanual repetitive alternating finger tapping (AFT) would reveal more arrhythmokinesis compared to bimanual @entity1847 (SFT), in @entity191 . METHODS: The variability of inter-strike interval (CVISI) and of amplitude (CVAMP) during AFT and SFT were measured on an engineered, MRI-compatible keyboard in sixteen @entity191 subjects off medication and in twenty-four age-matched controls. RESULTS: The CVISI and CVAMP of the @entity1316 ( @entity1316 ) and less affected (LA) sides in @entity191 subjects were greater during AFT than SFT (P   <   0.05). However, there was no difference between AFT and SFT for controls. Both CVISI and CVAMP were greater in the @entity1316 and LA hands of @entity191 subjects versus controls during AFT (P   <   0.01). The CVISI and CVAMP of the @entity1316 , but not the LA hand, were greater in PDs versus controls during SFT (P   <   0.05). Also, AFT, but not SFT, detected a difference between the @entity1316 and LA hands of PDs (P   <   0.01). CONCLUSIONS: Unimanual, repetitive alternating finger tapping brings out more arrhythmokinesis compared to bimanual, single finger tapping in PDs but not in controls. Arrhythmokinesis during unimanual, alternating finger tapping captured a significant difference between both the @entity1316 and LA hands of @entity191 subjects and controls, whereas that during a bimanual, single finger tapping task only distinguished between the @entity1316 hand and controls. Arrhythmokinesis underlies freezing of gait and may also underlie the freezing behavior documented in fine motor control if studied using a unimanual alternating finger tapping task.

title: Arrhythmokinesis is evident during unimanual not bimanual finger tapping in XXXX .

entities_list: @entity1847 :: ('MESH:D006226', 'Disease') :: ['single finger alternating hand tapping']

entities_list: @entity1316 :: ('MESH:D019964', 'Disease') :: ['MA', 'more affected']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", 'PD']

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']


abstract: AIM: To analyse the expression of multidrug resistance (MDR) related proteins at different steps in @entity14 . METHODS: The presence of three MDR related proteins ( @entity7895 , @entity11092 , and @entity8993 /MVP) was studied by means of immunohistochemistry in normal, adenomatous, and malignant colorectal epithelium. @entity406 fixed, paraffin embedded tissue sections of 17 samples of colorectal tissue were used (normal mucosa, n = 4; adjacent mucosa, n = 5; @entity652 , n = 5; @entity189 , n = 3). RESULTS: For all three proteins, expression was found in the surface epithelium and the upper parts of the crypts in normal colon. In the @entity652 , staining was seen along the complete length of the crypts. In the @entity189 analysed, all epithelium showed positive staining. Mucosa adjacent to either @entity189 or @entity652 showed staining patterns mostly resembling those of normal mucosa, but sometimes some extension of staining was seen along the crypt. CONCLUSIONS: These proteins already show increased expression in the @entity652 stage. In the absence of adequate mucin production in @entity652 , MDR related proteins could be an important factor in protecting the epithelium against further environmentally induced @entity74 . This could be one of the reasons why only about 5% of @entity2513 will actually progress to @entity189 .

title: Increased expression of multidrug resistance related proteins @entity7895 , XXXX , and @entity8993 /MVP occurs early in @entity14 .

entities_list: @entity406 :: ('MESH:D005557', 'Chemical') :: ['Formaldehyde']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas', 'carcinoma']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal carcinogenesis']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['genetic damage']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas', 'adenoma']

entities_list: @entity2513 :: ('MESH:C563365', 'Disease') :: ['colorectal adenomas']

answer: @entity11092 :: (4363,Gene) :: ['MRP1']


abstract: OBJECTIVE: To document the health resource utilization of @entity1 who repeatedly use emergency department services for @entity10 care. BACKGROUND: @entity1 with @entity10 who frequently use emergency department services may differ from @entity1 with more typical, episodic @entity2704 . Previous studies of health resource utilization have often failed to distinguish the high utilizer as a specific subset of the @entity2704 population. DESIGN: Retrospective review of urgent care/emergency department charts, clinic charts, and pharmacy rosters. @entity1 AND METHODS: @entity1 who made three or more visits for @entity10 to an urgent care/emergency department (UC/ED) facility for @entity10 over a 6-month study period were identified and designated as "repeaters" for this study. Pharmacy profiles and appointment histories of 52 of the 54 repeaters whose records were available were reviewed for the 12 months prior to the study period. RESULTS: Over the 6-month study period, 518 @entity1 visited the UC/ED 1004 times for primary @entity10 complaints. Fifty-four (10%) repeaters made 502 visits (50% of total visits; mean 9.3, range 3-50). In the 12 months prior to the study period, 52 of these repeaters made 1832 visits to the UC/ED or clinic (mean 35.2, range 0-178): 1458 (79.6%) were @entity10 related, and 1271 (69.4%) of all visits were to the UC/ED. An estimated 12-month cost for all visits was  183,760. Pharmacy rosters showed use of narcotics in 41 of the 52 @entity1 (annual mean +/- SD, 613 +/- 670 tablets), @entity1245 in 30 @entity1 (500 +/- 486 tablets), and butalbital products in 27 @entity1 (395 +/- 590 tablets). Mean daily use of all symptomatic medications combined was 3.9 +/- 3.2 doses/day. CONCLUSION: Health resource utilization of emergency department @entity10 repeaters is predominantly @entity10 -related acute care. Associated medication overuse is frequently present. Efforts to improve care for @entity1 with @entity10 will benefit from distinguishing the high utilizer as a subset of the @entity2704 population.

title: Health resource utilization of the emergency department XXXX "repeater".

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity1245 :: ('MESH:D001569', 'Chemical') :: ['benzodiazepines']

answer: @entity10 :: (MESH:D006261,Disease) :: ['headache']


abstract: To assess the incidence of the @entity301 and their outcome, angiographic evaluations were performed at the Department of Pediatrics, Kyushu University Hospital, from January 1973 to December 1994, on 313 @entity1 (189 @entity1 and 124 @entity1 ) after @entity573 ( @entity573 ). The age at onset of @entity573 and the interval from the onset to the first angiographic evaluation ranged from 0.2 to 12.3 years [2.2 +/- 2.0 years (mean +/- S.D.)] and from 0.1 to 15.3 years [2.4 +/- 3.0 years], respectively. Seventy-six of the 313 (24.3%) @entity1 studied had the @entity301 as the sequelae of @entity573 . Forty had left @entity301 alone, 10 right @entity301 alone, and 26 both @entity301 . Serial angiographic evaluation elucidated the difference of the fate of right and left @entity301 . Left @entity574 tended to regress gradually and to develop stenotic lesions. Complete occlusion of the left coronary arterial lesion was confirmed in only 2 of 66 @entity1 (3.0%). Right @entity574 , on the other hand, regressed relatively early in the subchronic phase and complete occlusion or segmental @entity850 was present in 9 of 36 @entity1 with the rate (25%) being higher than the left. The interval from the onset to the recognition of occlusion or segmental @entity850 ranged from 0.5 to 7.7 years (median 4.0 years). In 8 of 9 @entity1 with @entity1563 , @entity453 were also present. In spite of severe sequelae, @entity1 or young adolescents with cardiovascular system-related symptoms were unexpectedly rare.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Angiographic evaluation of XXXX due to @entity573 -natural history and @entity453 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'girls', 'boys']

entities_list: @entity573 :: ('MESH:C537014', 'Disease') :: ['KD', 'Kawasaki disease']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary lesions', 'coronary abnormalities']

entities_list: @entity1563 :: ('MESH:D054059', 'Disease') :: ['right coronary artery occlusion']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['left coronary arterial lesions']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity574 :: ('MESH:D003323', 'Disease') :: ['coronary aneurysms']

answer: @entity453 :: (MESH:D003324,Disease) :: ['coronary artery lesions']


abstract: PURPOSE: The risk for @entity204 in @entity1 with @entity995 is increased in those who present with metastatic disease, and the role of intensive chemotherapy and autologous hematopoietic stem cell rescue in these @entity1 remains unclear. DESIGN: Nonrandomized interventional case series. @entity1 : Four consecutive @entity1 with metastatic @entity995 . METHODS: We treated four @entity1 with @entity995 metastatic to the bone and bone marrow with intensive chemotherapy, consolidation with megatherapy, and autologous hematopoietic stem cell rescue. Chemotherapy included courses of @entity3003 and @entity2879 alternating with @entity786 , @entity2879 , and either @entity3003 or @entity900 . Radiation therapy was delivered to areas of bone metastases. MAIN OUTCOME MEASURES: @entity1 survival. RESULTS: All @entity1 completed and responded to the scheduled therapy; complete response of the @entity236 was documented after two courses of chemotherapy in all cases. Two @entity1 are long-term survivors. CONCLUSIONS: The treatment described has been successful in obtaining disease-free survival in @entity1 with metastatic @entity995 .

title: Treatment of metastatic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient', 'PARTICIPANTS']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow disease']

entities_list: @entity995 :: ('MESH:D012175', 'Disease') :: ['retinoblastoma']

answer: @entity995 :: (MESH:D012175,Disease) :: ['retinoblastoma']


abstract: BACKGROUND: @entity1149 ( @entity1149 ) with @entity75 ( @entity75 ) harboring an @entity470 ( @entity470 ) mutation shows good response to @entity4149 kinase inhibitors (TKIs). This study is to assess the appropriate timing of brain radiotherapy (RT) for asymptomatic @entity75 in @entity470 mutant @entity1149 @entity1 . METHODS: There were 628 @entity1 diagnosed with @entity470 mutant @entity1149 between October 2005 and December 2011. Treatment outcomes had been retrospectively evaluated in 96 @entity1 with asymptomatic @entity75 without prior TKI treatment. 39 @entity1 received first-line brain RT, 23 @entity1 received delayed brain RT, and 34 @entity1 did not receive brain RT. RESULTS: With a median follow-up of 26  months, the 2-year @entity1349 was 40.6  %. Univariate analyses revealed that ECOG performance status (p   =   0.006), other distant metastases (p   =   0.002) and first line systemic treatment (p   =   0.032) were significantly associated with @entity1349 ( @entity1349 ). Multivariate analyses revealed that other sites of distant metastases (p   =   0.030) were prognostic factor. The timing of brain RT was not significantly related to @entity1349 (p   =   0.246). The 2-year @entity75 progression-free survival (PFS) was 26.9  %. Brain RT as first-line therapy failed to demonstrate a significant association with @entity75 PFS (p   =   0.643). CONCLUSIONS: First-line brain RT failed to improve long-term survival in TKI-na  ve @entity470 mutant @entity1149 @entity1 with asymptomatic @entity75 . Prospective studies are needed to validate these clinical findings.

title: Radiotherapy for asymptomatic @entity75 in @entity470 mutant @entity1149 without prior XXXX kinase inhibitors treatment: a retrospective clinical study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['BM', 'brain metastasis']

entities_list: @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'Non-small cell lung cancer']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity4149 :: (D014443,Chemical) :: ['tyrosine']


abstract: Reducing the concentration of @entity4663 ( @entity8037 , @entity11667 , and @entity7224 ) in the body pool may slow the @entity5 process. Because dietary @entity8037 , @entity11667 , and @entity7224 contribute to the body pool of @entity4663 , quantifying them in the diet is important. Limited information about @entity4664 content of food is available, especially for diets in the United States. This brief report describes the development of a @entity4664 database linked to the Fred @entity5 Center food frequency questionnaire (FFQ). Values for @entity8037 , @entity11667 , and @entity7224 were calculated and reported per serving size (nmol/serving). Of the foods from the database that were evaluated, fresh and frozen @entity4336 contain the highest levels of @entity7224 (560,000 nmol/serving and 902,880 nmol/serving) and @entity11667 (137,682 nmol/serving and 221,111 nmol/serving), and green @entity3587 soup contains the highest concentration of @entity8037 (36,988 nmol/serving). The @entity4664 database and FFQ were tested with a convenience sample (n=165). Average daily @entity4664 intakes from the sample were: 159,133 nmol/day @entity7224 , 54,697 nmol/day @entity11667 , and 35,698 nmol/day @entity8037 . Orange and grapefruit juices contributed the greatest amount of @entity7224 (44,441 nmol/day) to the diet. Green @entity3587 contributed the greatest amount of @entity11667 (3,283 nmol/day) and ground meat contributed the greatest amount of @entity8037 (2,186 nmol/day). Development of this database linked to an FFQ provides a means of estimating @entity4664 intake and contributes to investigations relating @entity4663 to @entity5 .

title: Development of a XXXX database for assessing dietary intake.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Hutchinson Cancer', 'cancer']

entities_list: @entity8037 :: ('MESH:D013096', 'Chemical') :: ['spermine']

entities_list: @entity7224 :: ('MESH:D011700', 'Chemical') :: ['putrescine']

entities_list: @entity4663 :: ('MESH:D011073', 'Chemical') :: ['polyamines']

entities_list: @entity4664 :: ('CHEBI:60143', 'Chemical') :: ['polyamine']

entities_list: @entity11667 :: ('MESH:D013095', 'Chemical') :: ['spermidine']

answer: @entity4664 :: (CHEBI:60143,Chemical) :: ['polyamine']